SAB Biotherapeutics
SABS
SAB Biotherapeutics (SABS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.27
- EPS estimate
- −$0.28
- EPS surprise
- +4.59%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.28 | −$0.27 | +4.59% | $0.00 | SEC |
| Q1 2026 | May 12, 2026 | −$0.29 | −$0.35 | −22.04% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.80 | −$1.09 | −36.93% | $0.00 | SEC |
| Q1 2025 | May 9, 2025 | −$1.07 | −$0.56 | +47.79% | $0.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$1.16 | −$1.23 | −5.67% | $100,000.00 | SEC |
| Q3 2024 | Nov 6, 2024 | −$1.11 | −$1.12 | −1.27% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.15 | −$0.79 | +31.11% | $300,000.00 | SEC |
| Q1 2024 | May 20, 2024 | −$0.96 | −$0.54 | +43.75% | $944,575.00 | SEC |
| Q4 2023 | Mar 29, 2024 | −$0.62 | −$3.38 | −445.16% | $300,000.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$1.17 | −$1.00 | +14.29% | $633,500.00 | SEC |
| Q2 2022 | Aug 10, 2022 | −$1.30 | −$1.10 | +15.38% | $6.4M | — |
| Q1 2022 | May 12, 2022 | −$1.43 | $0.20 | +113.95% | $11.8M | — |
Quarterly revenue
Frequently asked questions
When did SAB Biotherapeutics (SABS) last report earnings?
SAB Biotherapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did SABS beat earnings estimates?
Yes. SAB Biotherapeutics reported EPS of −$0.27 for Q2 2026 against a −$0.28 estimate — a 4.59% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.